Comparison of abiraterone, enzalutamide, and apalutamide for metastatic hormone‐sensitive prostate cancer: A multicenter study

Documenti analoghi

• Assessment of Circulating Neuroendocrine Tumor Markers at Prostate Cancer Diagnosis: An Investigation of Prostate Cancer With Neuroendocrine Features
  di: Tatsuya Shimomura, et al.
  Pubblicazione: (2026)
• Prognostic model for second progression‐free survival and overall survival in patients with high‐risk metastatic hormone‐sensitive prostate cancer treated with abiraterone acetate and androgen deprivation therapy
  di: Shintaro Narita, et al.
  Pubblicazione: (2024)
• Real‐World Comparative Study of Apalutamide Versus Bicalutamide in Combination With Androgen Deprivation Therapy for Metastatic Hormone‐Sensitive Prostate Cancer
  di: Hidetsugu Takahashi, et al.
  Pubblicazione: (2026)
• Dose modification in enzalutamide and abiraterone plus prednisolone for castration‐resistant prostate cancer: A subanalysis from the ENABLE study for PCa
  di: Nobumichi Tanaka, et al.
  Pubblicazione: (2024)
• Androgen‐Deprivation Therapy and Dietary Habits Influence the Gut Microbial Environment in Patients With High‐Risk Localized Prostate Cancer
  di: Masanori Ishida, et al.
  Pubblicazione: (2025)